Ananya Ghosal, MAKAUT(WB)
Guidelines of ASCCP
The American cancer society (ASC) released the screening guideline for cervical cancer. The guideline initiates a shift in practice to Human papilloma Virus (HPV) screening at the age of 25-65 years in people with the cervix. The American Society for colposcopy and cervical pathology (ASCCP) acknowledges the risk and benefits of HPV cervical cancer screening which recognizes the barriers to extensive implementation issues, adoption, the effect of limited HPV vaccination, and underrepresented minorities.
ASCCP initiates cervical cancer screening for secondary prevention of cervical cancer and improving the screening process for unscreened and under-screened. HPV test doesn’t only anticipate the current disease but also predicts the future disease. By extending the screening interval for 3-5 years the risk increases of human Papillomavirus (hrHPV) testing. Cytology provides the current picture of the disease. Two types of HPV tests are provided by the Food and Drug Administration (FDA), which are Cobas HPV and BD Onclarity HPV. Beginning the screening process in people at the age of 25years with average risk Cervix. The ASCCP acknowledges the importance of the change primary HPV screening and recognizing logistical considerations. Self-sampling is approved by FDA.
Practical issues with adoption of HPV screening
ASCCP expects is to gain full access to primary HPV testing. They operationalize the screening strategy in private and public laboratories, need to allocate funds for human resources and capital expenses to acquire new equipment and adopt workflow. Community-based health centers, private offices, and health care systems need to cooperate with the laboratories to execute HPV primary screening with new codes to use cytology as a reflex test.
The 2012 guideline stated increasing in the testing interval based on the presence or absence of HPV results and HPV co-testing. HPV testing and a combination of cytology were still included in the 2012 guideline. Due to the global pandemic, the financial challenges to healthcare have increased and left the healthcare system financially devastated. Due to the financial state, the cost of transition primary HPV screening on healthcare centers may not viable. To convert primary HPV testing for cervical cancer, the primary HPV testing should be a slow process, allowing making adequate changes.
Effect of HPV vaccine
Secondary prevention has resulted in reduced deaths for cervical cancer by screening, detecting, and treatment. Most of the adults have not been vaccinated even when the vaccine was available. 21.5% of adults receive the advised number of doses and 39.9% of adults had received only one or more doses. The impact of immunization illustrated the reduction rate of cervical intraepithelial neoplasia grade 2.
Conclusion
The HPV vaccine improves and immunizes unit mature for screening age. To merge primary and secondary prevention, the transition to primary HPV screening programs and higher detection of CIN2+ has high immunization coverage in some countries than those adults screened at the age of 21years with cytology. The number of colposcopies to take one case CIN2+ has improved, that is, the ability to recognize the relevant disease. As per USPSTF guidelines, the ASCCP continued the acceptability of screening with cytology. The benefit of screening with cytology decreased and increasing harms, as the HPV immunization of the population, increased.
Also read: An intense embrace of two giants in cell division
Reference: Marcus, J. Z., Cason, P., Downs, L. S., Einstein, M. H., & Flowers, L. (2021). The ASCCP cervical cancer screening task force endorsement and opinion on the American cancer society updated cervical cancer screening guidelines. Journal of Lower Genital Tract Disease, 25(3), 187–191. https://doi.org/10.1097/LGT.0000000000000614
One thought on “Cervical cancer screening task: ASCCP”